Brief: Royalty Pharma Targets Mid-Teens Annual Shareholder Return Over Next 5 Years
11/09/2025 12:14
Sept 11 (Reuters) - Royalty Pharma PLC RPRX.O: ROYALTY PHARMA INVESTOR DAY HIGHLIGHTS STRONG GROWTH OUTLOOK AND COMPANY’S PLANS TO DRIVE VALUE CREATION ROYALTY PHARMA PLC - TARGETS MID-TEENS ANNUAL SHAREHOLDER RETURN OVER NEXT 5 YEARS ROYALTY PHARMA PLC - TARGETS $4.7 BILLION PORTFOLIO RECEIPTS OR MORE BY 2030 Source text: ID:nGNX6mjBcp Further company coverage: RPRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Royalty Pharma
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Royalty Pharma falls after Novartis' cholesterol drug fails in study
Brief: Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen
Teva's immune disorder drug meets main goal in mid-stage trial (updated)